Biotech News

Alkermes to Report Third Quarter Financial Results on November 3, 2026

Alkermes plc (ALKS)Alkermes plc2026-10-20 20:00 ESTEarnings

DUBLIN --(BUSINESS WIRE)--Oct. 20, 2026-- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company’s third quarter financial results. The webcast player and accompanying slides may be

Related news

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

HRMYHarmony Biosciences2026-10-20 12:05 EST

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

AXSMAxsome2026-10-07 11:00 EST

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

ABOSAcumen Pharmaceuticals2026-10-19 20:00 EST

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

NBIXNeurocrine Biosciences2026-10-12 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

ABOSAcumen Pharmaceuticals2026-08-05 20:00 EST

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

TSHATaysha Gene Therapies2026-08-11 20:00 EST

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GANXGain Therapeutics2026-08-11 11:00 EST

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

View all latest news

Alkermes plc

Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.

Recent company news

ALKSAlkermes plc2026-10-20 20:00 EST

Alkermes to Report Third Quarter Financial Results on November 3, 2026

ALKSAlkermes plc2026-10-13 11:00 EST

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

ALKSAlkermes plc2026-09-21 11:00 EST

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

ALKSAlkermes plc2026-09-16 11:00 EST

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

ALKSAlkermes plc2026-09-10 11:00 EST

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

Stock data

Close: 43.48 USD
Market cap: 6.89B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States